Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine.
The immunogenicity and reactogenicity, in British schoolchildren, of the newly introduced Danish-SSI 1331 BCG vaccine was compared with that of the previously used Glaxo-Evans 1077 BCG vaccine. Interferon-gamma (IFN-gamma) response to M. tuberculosis purified protein derivative (M.tb PPD) in a 6-day whole blood assay and delayed type hypersensitivity (DTH) to tuberculin PPD were determined before and 1 year after receiving BCG or no vaccination. Scar size was measured 1 year after vaccination. There was no evidence of a difference in immunogenicity (IFN-gamma and DTH conversion rates) but evidence of lower reactogenicity (scar size) with Danish-SSI 1331 compared to Glaxo-Evans 1077 vaccines.
Gorak-Stolinska
Patricia
P
London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, and Redbridge Primary Care Trust, Goodmayes Hospital, Essex, UK.
Weir
Rosemary E
RE
Floyd
Sian
S
Lalor
Maeve K
MK
Stenson
Sally
S
Branson
Keith
K
Blitz
Rose
R
Luke
Sarah
S
Nazareth
Bernadette
B
Ben-Smith
Anne
A
Fine
Paul E M
PE
Dockrell
Hazel M
HM
D001500:BCG Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D002648:Child; D002921:Cicatrix; D003718:Denmark; D006801:Humans; D006968:Hypersensitivity, Delayed; D007371:Interferon-gamma / Q000378:metabolism; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D014373:Tuberculin / Q000276:immunology; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*; D006113:United Kingdom; D014611:Vaccination
D001500:BCG Vaccine; D014373:Tuberculin; D007371:Interferon-gamma